Neogenomics (NEO) Return on Sales (2010 - 2026)

Neogenomics has reported Return on Sales for 17 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q4 2025, with the low at 0.0% in Q1 2022.
• Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
• The largest YoY upside for Return on Sales was 0 bps in 2022 against a maximum downside of 1 bps in 2022.
• Neogenomics' Return on Sales stood at 0.0% in 2022, then jumped by 44 bps to 0.0% in 2023, then climbed by 3 bps to 0.0% in 2024, then surged by 42 bps to 0.0% in 2025, then plunged by 76 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.